Spoken Alpha
BMY
BRISTOL MYERS SQUIBB CO
Overview
Bristol Myers Squibb manufactures and sells pharmaceutical products for oncology, immunology, cardiovascular disease, and cell therapy, primarily to hospitals, healthcare providers, and patients through wholesalers and direct distribution channels.
BRISTOL MYERS SQUIBB CO is a Healthcare company operating in Drug Manufacturers - General with a $130.57B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 28, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-07-3019 Q&A exchanges
- Q1 FY2026Earnings2026-04-3011 Q&A exchanges
- Q4 FY2025Earnings2026-02-0519 Q&A exchanges
- Q3 FY2025Earnings2025-10-3014 Q&A exchanges
- Q2 FY2025Earnings2025-07-3114 Q&A exchanges
- Q1 FY2025Earnings2025-04-2425 Q&A exchanges
- Q4 FY2024Earnings2025-02-0623 Q&A exchanges
- Q3 FY2024Earnings2024-10-3120 Q&A exchanges
- Q2 FY2024Earnings2024-07-2637 Q&A exchanges
- Q1 FY2024Earnings2024-04-2518 Q&A exchanges
- Q4 FY2023Earnings2024-02-0232 Q&A exchanges
- Q3 FY2023Earnings2023-10-2629 Q&A exchanges
- Q2 FY2023Earnings2023-07-2726 Q&A exchanges
- Q1 FY2023Earnings2023-04-2717 Q&A exchanges
- Q4 FY2022Earnings2023-02-0215 Q&A exchanges
- Q3 FY2022Earnings2022-10-2616 Q&A exchanges
- Q2 FY2022Earnings2022-07-2728 Q&A exchanges
- Q1 FY2022Earnings2022-04-2917 Q&A exchanges
- Q4 FY2021Earnings2022-02-0416 Q&A exchanges
- Q3 FY2021Earnings2021-10-2719 Q&A exchanges
- Q2 FY2021Earnings2021-07-2819 Q&A exchanges
- Q1 FY2021Earnings2021-04-2921 Q&A exchanges
History
Earnings history
- Q3 FY20262026-10-28EPS— vs $1.68—Rev— vs ——EODHD
- Q2 FY20262026-07-29EPS$2.04 vs $1.59+28.3%Rev$12.97B vs ——EODHD
- Q1 FY20262026-04-29EPS$1.58 vs $1.42+11.3%Rev$11.49B vs ——EODHD
- Q4 FY20252026-02-04EPS$1.26 vs $1.20+5.0%Rev$12.50B vs ——EODHD
- Q3 FY20252025-10-29EPS$1.63 vs $1.52+7.2%Rev$12.22B vs ——EODHD
- Q2 FY20252025-07-30EPS$1.46 vs $1.10+32.7%Rev$12.27B vs ——EODHD
- Q1 FY20252025-04-23EPS$1.80 vs $1.50+20.0%Rev$11.20B vs ——EODHD
- Q4 FY20242025-02-05EPS$1.67 vs $1.47+13.6%Rev$12.34B vs ——EODHD
- Q3 FY20242024-10-30EPS$1.80 vs $1.50+20.0%Rev$11.89B vs ——EODHD
- Q2 FY20242024-07-25EPS$2.07 vs $1.63+27.0%Rev$12.20B vs ——EODHD
- Q1 FY20242024-04-24EPS$-4.40 vs $-4.14-6.3%Rev$11.87B vs ——EODHD
- Q4 FY20232024-02-01EPS$1.59 vs $1.43+11.2%Rev$11.48B vs ——EODHD
- Q3 FY20232023-10-25EPS$2.00 vs $1.77+13.0%Rev$10.97B vs ——EODHD
- Q2 FY20232023-07-26EPS$1.75 vs $1.99-12.1%Rev$11.23B vs ——EODHD
- Q1 FY20232023-04-26EPS$2.05 vs $1.97+4.1%Rev$11.34B vs ——EODHD
- Q4 FY20222023-02-01EPS$1.82 vs $1.73+5.2%Rev$11.41B vs ——EODHD
- Q3 FY20222022-10-24EPS$1.99 vs $1.83+8.7%Rev$11.22B vs ——EODHD
- Q2 FY20222022-07-26EPS$1.93 vs $1.80+7.2%Rev$11.89B vs ——EODHD
- Q1 FY20222022-04-28EPS$1.96 vs $1.90+3.2%Rev$11.65B vs ——EODHD
- Q4 FY20212022-02-03EPS$1.83 vs $1.80+1.7%Rev$11.98B vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-28 | — | $1.68 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $2.04 | $1.59 | +28.3% | $12.97B | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $1.58 | $1.42 | +11.3% | $11.49B | — | — | EODHD |
| Q4 FY2025 | 2026-02-04 | $1.26 | $1.20 | +5.0% | $12.50B | — | — | EODHD |
| Q3 FY2025 | 2025-10-29 | $1.63 | $1.52 | +7.2% | $12.22B | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $1.46 | $1.10 | +32.7% | $12.27B | — | — | EODHD |
| Q1 FY2025 | 2025-04-23 | $1.80 | $1.50 | +20.0% | $11.20B | — | — | EODHD |
| Q4 FY2024 | 2025-02-05 | $1.67 | $1.47 | +13.6% | $12.34B | — | — | EODHD |
| Q3 FY2024 | 2024-10-30 | $1.80 | $1.50 | +20.0% | $11.89B | — | — | EODHD |
| Q2 FY2024 | 2024-07-25 | $2.07 | $1.63 | +27.0% | $12.20B | — | — | EODHD |
| Q1 FY2024 | 2024-04-24 | $-4.40 | $-4.14 | -6.3% | $11.87B | — | — | EODHD |
| Q4 FY2023 | 2024-02-01 | $1.59 | $1.43 | +11.2% | $11.48B | — | — | EODHD |
| Q3 FY2023 | 2023-10-25 | $2.00 | $1.77 | +13.0% | $10.97B | — | — | EODHD |
| Q2 FY2023 | 2023-07-26 | $1.75 | $1.99 | -12.1% | $11.23B | — | — | EODHD |
| Q1 FY2023 | 2023-04-26 | $2.05 | $1.97 | +4.1% | $11.34B | — | — | EODHD |
| Q4 FY2022 | 2023-02-01 | $1.82 | $1.73 | +5.2% | $11.41B | — | — | EODHD |
| Q3 FY2022 | 2022-10-24 | $1.99 | $1.83 | +8.7% | $11.22B | — | — | EODHD |
| Q2 FY2022 | 2022-07-26 | $1.93 | $1.80 | +7.2% | $11.89B | — | — | EODHD |
| Q1 FY2022 | 2022-04-28 | $1.96 | $1.90 | +3.2% | $11.65B | — | — | EODHD |
| Q4 FY2021 | 2022-02-03 | $1.83 | $1.80 | +1.7% | $11.98B | — | — | EODHD |
Source: EODHD. BMY reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Christopher S BoernerCEO2 yr 10 mo22 callsCurrent
- David Elkins VCFO6 yr 10 mo22 callsCurrent
- Benjamin HickeyPresident2 yr 7 mono recorded callsCurrent
- Lynelle HochPresident2 yr 9 mono recorded callsCurrent
- Hiroshi Chris ShibutaniEVP, Chief Strategy Officer1 yr 3 mono recorded callsCurrent
- Ahn Amanda PooleEVP, Chief People Officer1 yr 6 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BMY.
$ curl https://api.spokenalpha.com/v1/companies/BMYFAQ
Frequently asked about BMY
Where can I find BRISTOL MYERS SQUIBB CO's (BMY) earnings call transcripts?
Spoken Alpha indexes BMY's earnings call transcripts at https://spokenalpha.com/companies/BMY. Each call links to attributed speakers and parsed analyst Q&A. BRISTOL MYERS SQUIBB CO's own investor relations page is at https://www.bms.com/investors.html.
When was BRISTOL MYERS SQUIBB CO's most recent earnings call?
BRISTOL MYERS SQUIBB CO (BMY) held its most recent earnings call on 2026-07-30, covering fiscal Q2 2026.
What sector is BMY in?
BRISTOL MYERS SQUIBB CO (BMY) operates in the Healthcare sector (Drug Manufacturers - General industry).